Insider Transactions in Q2 2021 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,007
+0.41%
|
$21,147
$21.09 P/Share
|
|
Jun 28
2021
|
Apple Tree Partners Iv, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
5,830,203
-100.0%
|
-
|
|
Jun 01
2021
|
Kevin Bitterman Director |
SELL
Open market or private sale
|
Indirect |
17,489
-100.0%
|
$454,714
$26.28 P/Share
|
|
Jun 01
2021
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,055
-1.83%
|
$79,430
$26.24 P/Share
|
|
May 03
2021
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,200
-64.92%
|
$126,000
$30.56 P/Share
|
|
May 03
2021
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,200
+39.36%
|
$29,400
$7.01 P/Share
|
|
May 03
2021
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,055
-1.8%
|
$91,650
$30.56 P/Share
|
|
Apr 01
2021
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-63.53%
|
$1,400,000
$28.96 P/Share
|
|
Apr 01
2021
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+48.89%
|
$350,000
$7.01 P/Share
|
|
Apr 01
2021
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,055
-1.76%
|
$85,540
$28.75 P/Share
|